COSCIENS Biopharma Inc. (TSX:CSCI)
Canada · Delayed Price · Currency is CAD 8.75
0.00 (0.00%)
Oct 1, 2026, 2:13 PM EST
COSCIENS Biopharma Ratios and Metrics
Market cap in millions CAD. Fiscal year is January - December.
Millions CAD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 9 | 9 | 7 | 12 | 21 | 55 | |
Market Cap Growth | -24.55% | 30.63% | -44.54% | -40.23% | -62.20% | 63.20% |
Enterprise Value | 4 | 0 | -18 | -40 | -53 | -30 |
Last Close Price | 8.75 | 8.52 | 11.58 | 30.84 | 51.60 | 136.50 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 0.94 | - | - | - | 4.47 | - |
Forward PE | - | 0.64 | 0.64 | 0.64 | 0.64 | 0.64 |
PS Ratio | 0.70 | 0.88 | 0.50 | 1.32 | 1.06 | 8.30 |
PB Ratio | 0.41 | 1.72 | 0.37 | 0.45 | 0.43 | 0.82 |
P/TBV Ratio | 0.41 | 1.72 | 0.37 | 0.45 | 0.43 | 0.99 |
P/FCF Ratio | - | - | - | - | 3.13 | - |
P/OCF Ratio | - | - | - | - | 2.95 | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 0.32 | 0.02 | - | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.13 | 0.56 | 0.18 | 0.08 | 0.01 | 0.00 |
Debt / EBITDA Ratio | - | - | - | - | 0.03 | - |
Debt / FCF Ratio | - | - | - | - | 0.04 | - |
Net Debt / Equity Ratio | -0.22 | -1.34 | -1.07 | -0.24 | -1.41 | -1.23 |
Net Debt / EBITDA Ratio | 0.64 | 0.54 | 1.62 | 1.56 | -8.71 | 7.64 |
Net Debt / FCF Ratio | 0.88 | 0.56 | 0.90 | 1.51 | -10.24 | 7.57 |
Asset Turnover | 0.38 | 0.27 | 0.33 | 0.18 | 0.21 | 0.09 |
Inventory Turnover | 3.41 | 2.47 | 1.45 | 1.98 | 39.84 | 1.92 |
Quick Ratio | 3.42 | 2.37 | 2.61 | 5.32 | 7.49 | 8.88 |
Current Ratio | 4.33 | 3.18 | 3.32 | 8.59 | 7.88 | 9.12 |
Return on Equity (ROE) | -52.83% | -121.84% | -89.54% | -12.27% | 7.77% | -25.28% |
Return on Assets (ROA) | -16.71% | -23.10% | -21.13% | -7.25% | 3.97% | -9.25% |
Return on Invested Capital (ROIC) | -52.03% | - | -131.39% | -661.76% | - | - |
Return on Capital Employed (ROCE) | -37.40% | -58.60% | -35.70% | -20.60% | 8.80% | -12.00% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 1, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 106.65% | -157.09% | -318.27% | -36.88% | 22.35% | -19.17% |
FCF Yield | -61.45% | -139.21% | -327.00% | -34.96% | 31.92% | -19.73% |
Buyback Yield / Dilution | -0.67% | -22.62% | -39.74% | 0.39% | -61.37% | -179.74% |